Cargando…
SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis
INTRODUCTION: Laser interstitial thermal therapy (LITT) is a minimally-invasive treatment option often used for patients with deep-seated intracranial lesions. It has been implemented as a definitive treatment for radiation necrosis (RN), which occurs in 9–14% of patients after stereotactic radiosur...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351187/ http://dx.doi.org/10.1093/noajnl/vdab071.102 |
_version_ | 1783735918460403712 |
---|---|
author | Lerner, Emily Srinivasan, Ethan Sankey, Eric Grabowski, Matthew Griffin, Andrew Howell, Elizabeth Otvos, Balint Tsvankin, Vadim Akit, Ahmet Joshi, Krishna Barnett, Gene Fecci, Peter Mohammadi, Alireza |
author_facet | Lerner, Emily Srinivasan, Ethan Sankey, Eric Grabowski, Matthew Griffin, Andrew Howell, Elizabeth Otvos, Balint Tsvankin, Vadim Akit, Ahmet Joshi, Krishna Barnett, Gene Fecci, Peter Mohammadi, Alireza |
author_sort | Lerner, Emily |
collection | PubMed |
description | INTRODUCTION: Laser interstitial thermal therapy (LITT) is a minimally-invasive treatment option often used for patients with deep-seated intracranial lesions. It has been implemented as a definitive treatment for radiation necrosis (RN), which occurs in 9–14% of patients after stereotactic radiosurgery (SRS) for brain metastases (BM). Medical management (MM) with steroids is a common first-line therapy, with variable response and numerous side effects, especially regarding immunotherapy. METHODS: Patients with biopsy-proven RN after SRS for BM who received LITT or MM at two academic centers were retrospectively reviewed. Treatment failure was defined as radiographic progression that necessitated a change in management. Measurements of total (TLV) and contrast-enhancing lesion volume (ceLV) were obtained from MRI by semi-automated analysis using the BrainLab iPlan Cranial 3.0 software. RESULTS: Seventy-two patients were followed for 10.0 (4.2–25.1) months and 57 (79%) received LITT. Steroid cessation occurred at a median of 37 days post-LITT compared to 245 days after MM (p<0.01). On Kaplan-Meier analyses, there was no significant difference between the two groups in overall survival (LITT median of 15.2 months vs 11.6 months, p = 0.60) or freedom from local progression (13.6 months vs. 7.06 months), though LITT trended to show a benefit in both metrics. When controlled for follow-up duration, patients treated with LITT were three times more likely to be weaned off steroids prior to the study endpoint compared to those who were medically managed (p=0.003). The LITT cohort demonstrated a general radiographic trend of initially increased CeLV followed by contraction, with significant decreases from pre-operative at 10–12 months (p<0.01). The MM group did not demonstrate any statistically significant radiographic trends. CONCLUSION: These results suggest that LITT for RN significantly reduces the time to steroid cessation and characterize a stereotyped radiographic response to LITT. Future prospective studies will be important to their validation. |
format | Online Article Text |
id | pubmed-8351187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-83511872021-08-09 SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis Lerner, Emily Srinivasan, Ethan Sankey, Eric Grabowski, Matthew Griffin, Andrew Howell, Elizabeth Otvos, Balint Tsvankin, Vadim Akit, Ahmet Joshi, Krishna Barnett, Gene Fecci, Peter Mohammadi, Alireza Neurooncol Adv Supplement Abstracts INTRODUCTION: Laser interstitial thermal therapy (LITT) is a minimally-invasive treatment option often used for patients with deep-seated intracranial lesions. It has been implemented as a definitive treatment for radiation necrosis (RN), which occurs in 9–14% of patients after stereotactic radiosurgery (SRS) for brain metastases (BM). Medical management (MM) with steroids is a common first-line therapy, with variable response and numerous side effects, especially regarding immunotherapy. METHODS: Patients with biopsy-proven RN after SRS for BM who received LITT or MM at two academic centers were retrospectively reviewed. Treatment failure was defined as radiographic progression that necessitated a change in management. Measurements of total (TLV) and contrast-enhancing lesion volume (ceLV) were obtained from MRI by semi-automated analysis using the BrainLab iPlan Cranial 3.0 software. RESULTS: Seventy-two patients were followed for 10.0 (4.2–25.1) months and 57 (79%) received LITT. Steroid cessation occurred at a median of 37 days post-LITT compared to 245 days after MM (p<0.01). On Kaplan-Meier analyses, there was no significant difference between the two groups in overall survival (LITT median of 15.2 months vs 11.6 months, p = 0.60) or freedom from local progression (13.6 months vs. 7.06 months), though LITT trended to show a benefit in both metrics. When controlled for follow-up duration, patients treated with LITT were three times more likely to be weaned off steroids prior to the study endpoint compared to those who were medically managed (p=0.003). The LITT cohort demonstrated a general radiographic trend of initially increased CeLV followed by contraction, with significant decreases from pre-operative at 10–12 months (p<0.01). The MM group did not demonstrate any statistically significant radiographic trends. CONCLUSION: These results suggest that LITT for RN significantly reduces the time to steroid cessation and characterize a stereotyped radiographic response to LITT. Future prospective studies will be important to their validation. Oxford University Press 2021-08-09 /pmc/articles/PMC8351187/ http://dx.doi.org/10.1093/noajnl/vdab071.102 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Supplement Abstracts Lerner, Emily Srinivasan, Ethan Sankey, Eric Grabowski, Matthew Griffin, Andrew Howell, Elizabeth Otvos, Balint Tsvankin, Vadim Akit, Ahmet Joshi, Krishna Barnett, Gene Fecci, Peter Mohammadi, Alireza SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title | SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title_full | SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title_fullStr | SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title_full_unstemmed | SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title_short | SURG-09. Benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
title_sort | surg-09. benefits of laser interstitial thermal therapy in the treatment of biopsy-proven radiation necrosis |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351187/ http://dx.doi.org/10.1093/noajnl/vdab071.102 |
work_keys_str_mv | AT lerneremily surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT srinivasanethan surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT sankeyeric surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT grabowskimatthew surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT griffinandrew surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT howellelizabeth surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT otvosbalint surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT tsvankinvadim surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT akitahmet surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT joshikrishna surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT barnettgene surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT feccipeter surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis AT mohammadialireza surg09benefitsoflaserinterstitialthermaltherapyinthetreatmentofbiopsyprovenradiationnecrosis |